Home » Newsletters » BioWorld Science

BioWorld Science

April 17, 2002

View Archived Issues

The role of statins in the treatment of multiple sclerosis

Alizyme reviews 2001, profiles future expectations

Lilly and Ligand extend collaboration in type 2 diabetes, cardiovascular disorders and obesity

BioMarin and Genzyme initiate rolling BLA for Aldurazyme

Positive phase I/IIa data reported for NCX-4016 in symptomatic peripheral arterial disease

Adolor's alvimopan will be codeveloped with GSK

Oral PTH analogue for osteoporosis licensed to GlaxoSmithKline

Late-breaking AACR presentation describes preclinical profile of new orally active mTOR inhibitor

FDA grants priority review to Arimidex in early breast cancer

Abgenix and Diabetogen enter antibody therapy collaboration for autoimmune disease

Go-ahead received for group A Streptococcus vaccine trial

Glivec approved in Switzerland for GISTs

Phase III U.S. trials start for hepatitis C combination therapy in nonresponders

Arcoxia granted major approval for relief of arthritis and pain

Novel VTA from Oxigene markedly reduces tumor blood flow and exerts potent antitumor effects

Semisynthetic andrographolide analogue with immunomodulating and antitumor activity

AACR presentations provide further preclinical characterization of epothilone D

AVI-4126 may be useful alone or in combination in the treatment of prostate cancer

Vanilloid receptor antagonists possessing analgesic and antiinflammatory properties

Novel factor Xa inhibitors identified at Morphochem

Boehringer Ingelheim claims new series of sodium channel blockers

Estrogen receptor modulators and their use described by Akzo Nobel team

Dipeptide inhibitors of apoptosis in development at Cytovia

Integrin inhibitors with a biphenyl structure designed at Merck

New delivery agents reported in recent patent by Emisphere

PNU-183792 found to be active in an animal model of lethal MCMV infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...